A 42-year-old man presented with a 3-month history of persistent ulcerated nodules (Fig 1) . History was relevant for deployment to the Middle East, Africa, Turkey, and South East Asia. He also reported skinning squirrels and butchering hogs on his farm in Missouri. Review of systems found intermittent fevers and night sweats. Prior treatment included multiple oral antibiotics without improvement. Examination found ulcerated, firm, pink nodules on the right forearm, elbow, and arm in sporotrichoid distribution without palpable lymphadenopathy. A punch biopsy was obtained and staining performed, including hematoxylin-eosin (Fig 2, A) , CD30 (Fig 2, B) , anaplastic lymphoma kinase (ALK-1) (Fig 2, C; control, Fig 2, D) . A. Bexarotene gel e Incorrect. Bexarotene is FDA approved for the topical treatment of cutaneous lesions in patients with cutaneous T-cell lymphoma, stage 1A and 1B, who have refractory or persistent disease after other therapies or who have not tolerated other therapies. Data regarding the use of topical bexarotene gel are limited to case reports and the control arm of the ALCANZA trial in which the response rate was low. 3 B. BV e Correct. BV is an anti-CD30 monoclonal antibody that is FDA approved for the treatment of adult patients with PC-ALCL who have received at least 1 prior systemic therapy. 4 Approval was based on a phase 3, randomized clinical trial (ALCANZA), which randomized patients to receive BV or either methotrexate or bexarotene. BV resulted in complete resolution of skin involvement in 10 of 16 patients (63%) with PC-ALCL. 3 C. Imiquimod e Incorrect. The use of topical imiquimod has been described in case reports and case series; however, it is not FDA approved for PC-ALCL. 5 D. Interferon e Incorrect. Interferon is not FDA approved for PC-ALCL, and because of its toxicity, it is generally reserved for patients who progress on or who are intolerant to methotrexate or bexarotene.
E. Methotrexate e Incorrect. Methotrexate is not FDA approved for PC-ALCL. However, low-dose (less than 25 mg/wk) is considered first-line therapy for multifocal PC-ALCL when radiotherapy is not feasible. 2 Patient Course: The patient underwent local radiation to the right arm, which he tolerated well, but new lesions developed proximal to the radiated port. Thus, he was started on brentuximab for 4 cycles and experienced complete remission.
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